COVID-19 neutralizing antibodies predict disease severity and survival

By W. Garcia-Beltran, Evan C. Lam, M. Astudillo, Diane Yang, T. Miller, J. Feldman, B. Hauser, Timothy M. Caradonna, K. Clayton, Adam D Nitido and 10 more. medRxiv, 2020

682 citations recorded by the source corpus.

COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting protection from reinfection by this strain. However, SARS-CoV-2 sera was unable to cross-neutralize a highly-homologous pre-emergent bat coronavirus, WIV1-CoV, that has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.

Subfields: Infectious Diseases, Modeling and Simulation

View Paper: https://www.semanticscholar.org/paper/3e53fd73a4faaa1fb77faa476660ed7469017560

Citations in the corpus